Elacestrant Improves Outcomes for Certain Patients With Breast Cancer
October 29th 2021The study was designed to evaluate elacestrant as a monotherapy compared to the standard of care for the treatment of estrogen receptor-positive/human epidermal growth factor receptor 2 advanced or metastatic breast cancer.
Read More
Psychedelic Drug in Early Stages of Development Could Have Potential for Postpartum Depression
October 28th 2021Nathan Bryson, PhD, chief scientific officer of Field Trip Health, said the company's new psychedelic compound, FT-104, could have potential uses in the treatment of postpartum depression.
Watch
The Role of Student Pharmacists in the Immunization Process at Northeastern University
Read More
Oncology Overview: Sacituzumab Govitecan-hziy (Trodelvy) for Triple-Negative Breast Cancer
October 27th 2021Sacituzumab govitecan-hziy (Trodelvy) is indicated for the treatment of patients with triple-negative breast cancer who have received 2 prior therapies at minimum for metastatic disease.
Read More